<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744354</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0715</org_study_id>
    <secondary_id>08-1073</secondary_id>
    <nct_id>NCT00744354</nct_id>
  </id_info>
  <brief_title>Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of&#xD;
      the enzymes needed for cell growth. Bortezomib may also stop the growth of multiple myeloma&#xD;
      by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin&#xD;
      hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving doxorubicin hydrochloride&#xD;
      liposome together with vorinostat and bortezomib may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat and to&#xD;
      see how well it works when given together with bortezomib and doxorubicin hydrochloride&#xD;
      liposome in treating patients with relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of vorinostat when added to the standard regimen&#xD;
           of bortezomib and pegylated liposomal doxorubicin hydrochloride in patients with&#xD;
           relapsed or refractory multiple myeloma.&#xD;
&#xD;
        -  To identify the dose-limiting toxicities of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To gain preliminary evidence of antitumor activity of this regimen in these patients.&#xD;
&#xD;
        -  To assess the degree of proteasome inhibition achieved with this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  To evaluate the accumulation of acetylated alpha-tubulin after treatment with&#xD;
           vorinostat.&#xD;
&#xD;
        -  To evaluate overall survival, time to progression, and progression-free survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose escalation study of vorinostat.&#xD;
&#xD;
      Patients receive oral vorinostat once daily on days 1,2; 4,5; 8, 9; 11, 12; bortezomib IV on&#xD;
      days 1, 4, 8, and 11, and pegylated liposomal doxorubicin hydrochloride IV on day 4. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected periodically for proteasome inhibition assays and acetylated&#xD;
      alpha-tubulin studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 1 and 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drugs unavailable- study terminated 1/2/18&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of vorinostat</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Non-Randomized Open Label Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11</description>
    <arm_group_label>Non-Randomized Open Label Single Arm</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
    <description>Intravenous infusion, 30mg/m2, Day 4, each cycle</description>
    <arm_group_label>Non-Randomized Open Label Single Arm</arm_group_label>
    <other_name>Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.</description>
    <arm_group_label>Non-Randomized Open Label Single Arm</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma&#xD;
&#xD;
               -  Relapsed or refractory disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ANC ≥ 1.0 x 10^9/L (no granulocyte growth factor support, e.g., G-CSF or GM-CSF&#xD;
             allowed)&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L (erythropoietin allowed, no platelet or RBC transfusion&#xD;
             within the past 2 weeks)&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (erythropoietin allowed, no platelet or RBC transfusion within the&#xD;
             past 2 weeks)&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  LVEF ≥ 45% by MUGA or ECHO&#xD;
&#xD;
          -  Symptomatic neuropathy &lt; grade 2&#xD;
&#xD;
          -  No known history of HIV&#xD;
&#xD;
          -  No active or serious infection, medical or psychiatric illness that would preclude&#xD;
             study participation&#xD;
&#xD;
          -  No active hepatitis B or C infection&#xD;
&#xD;
          -  No other prior or concurrent malignancy except for adequately treated basal cell or&#xD;
             squamous cell carcinoma of the skin, in situ malignancy, low-risk prostate cancer&#xD;
             after curative therapy, or other cancer for which the patient has been disease-free&#xD;
             for ≥ 3 years&#xD;
&#xD;
          -  No history of hypersensitivity reaction to bortezomib or any of its components (boron,&#xD;
             mannitol), vorinostat, doxorubicin hydrochloride, or any of the components of PLD&#xD;
&#xD;
          -  No serum potassium ≤ 3.0 or serum magnesium ≤ 1.6 that cannot be corrected with&#xD;
             supplementation are excluded&#xD;
&#xD;
          -  Patients must have adequate cardiovascular function, defined by all of the following:&#xD;
&#xD;
               -  No EKG evidence of active, clinically significant conduction system abnormalities&#xD;
&#xD;
               -  No EKG evidence of QTc prolongation &gt; grade 2&#xD;
&#xD;
          -  NOTE: Any EKG abnormality at screening has to be documented by the investigator as not&#xD;
             medically significant.&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No limit to number of prior treatment regimens&#xD;
&#xD;
          -  At least 30 days since prior therapy and recovered&#xD;
&#xD;
          -  At least 3 months since prior autologous stem cell transplantation and recovered&#xD;
&#xD;
          -  Prior allogeneic stem cell or bone marrow transplantation allowed provided the&#xD;
             following criteria are met:&#xD;
&#xD;
               -  More than 1 year since transplantation&#xD;
&#xD;
               -  No longer receiving immunosuppressive therapy or treatment for graft-versus-host&#xD;
                  disease (GVHD) prophylaxis&#xD;
&#xD;
               -  No active GVHD&#xD;
&#xD;
               -  No active, uncontrolled infections&#xD;
&#xD;
          -  No major surgery within the past 3 weeks&#xD;
&#xD;
          -  No prior anthracycline dose &gt; 360 mg/m^2 for doxorubicin hydrochloride (including&#xD;
             pegylated liposomal doxorubicin hydrochloride [PLD]) or 720 mg/m^2 for epirubicin&#xD;
             hydrochloride&#xD;
&#xD;
          -  No prior or concurrent histone deacetylase inhibitor (e.g., valproic acid)&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) during course 1&#xD;
&#xD;
          -  No other concurrent investigational or anticancer agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandi Reeves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://unclineberger.org</url>
    <description>Web address for UNC Lineberger Comprehensive Cancer Center</description>
  </link>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

